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The Production of Ly-1-,2+ Suppressors of Delayed Sensitivity Precedes
the Production of Suppressors of Protective Immunity
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A central problem in tumor immunology has been to explain how immuno-
genic tumors escape destruction by the immune defenses of their immunocom-
petent hosts. The results of studies performed during the past few years in this
laboratory (reviewed in 1) support thehypothesis that certain tumors withtumor-
specific, transplantation antigens avoid destruction by the immune response of
their hosts by evoking the production of a population of suppressor T cells that
functions to downregulate the immune response before enough effector T cells
are generated to cause tumor regression. These published studies (2, 3) show
that growth ofthe immunogenic tumors under investigation evokes the genera-
tion of an underlying state of concomitant immunity, which develops progres-
sively between days 6 and 9 of tumor growth, and which is mediated by Ly-2+
effector T cells. After day 9, however, there is progressive loss of effector T
cells, and this is temporarily associated with the progressive acquisition of Ly-
1+,2- suppressor T cells that are functionally defined by their ability to inhibit,
on passive transfer, the expression of adoptive immunity against an established
tumor in immunodepressed test recipients. It was postulated, on the basis of
these and other results (1), that the loss ofeffector T cells results from negative
regulation by tumor-induced suppressor T cells.
However, other investigators have described the generation ofa different type
ofsuppressor Tcell in mice bearing progressive immunogenic tumors (reviewed
in 4). This second type ofsuppressor T cell displays the Ly1-,2+, I-J' membrane
phenotype, is generated at a very early stage oftumor growth, and is defined by
its ability to suppress, on passive transfer, a delayed-type hypersensitivity (DTH)'
reaction to tumor antigens in tumor-immune recipients. Because these suppres-
sors ofDTH are generated progressively during the first 6-7 d of tumor growth
(5, 6), but are then progressively lost (6), it seems unlikely that they would exert
a meaningful suppressor function in those situations where a tumor evokes the
generation of a state of concomitant antitumor immunity that does not peak
until day 9 of tumor growth, and does not undergo decay until after days 9-12.
The purpose of the study reported here, therefore, was to determine whether
both types of suppressor T cells are generated in response to growth of a
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chemically induced tumor that can evoke the generation ofconcomitant immu-
nity. It will show that Ly-1 -,2' T cells that can suppress a tumor-specific DTH
reaction, and Ly-1 +,2- suppressor T cells that can suppress the expression of
adoptive immunity, are generated in sequence in response to progressive growth
of the immunogenic BALB/c Meth A fibrosarcoma. It will also show that the T
cell suppressors that can suppress DTH fail to suppress the expression ofadoptive
immunity, and conversely, that T cells that suppress adoptive immunity fail to
suppress DTH. It will be argued that because T cells that can suppress adoptive
immunity are generated during the progressive decay of a concomitant immune
response, it is they, rather than the earlier generated Tcell suppressors ofDTH,
that serve best to explain the downregulation of concomitant immunity and
failure ofthis form of immunity to cause tumor regression.
Materials and Methods
Mice.
￿
Specific pathogen-free CB6F1 (BALB/c X C57BL/6) and BALB/c female mice
were supplied by the Trudeau Institute Animal Breeding Facility. The mice were free of
viral pathogens, as evidenced by the results of routine serological screening performed by
the Diagnostic Testing Service of Microbiological Associates, Bethesda, MD.
Tumor.
￿
The methylcholanthrene-induced Meth A fibrosarcoma syngeneic in BALB/c
mice was used in this study. The tumor, grown as ascites in the peritoneal cavities of
syngeneic hosts, was harvested in heparinized (5 U/ml) PBS, the cells were pooled, washed
in PBS, resuspended in Fisher's medium (Grand Island Biological Co., Grand Island, NY)
containing 20% FCS and 10% DMSO, and were cryopreserved in small volumes over
liquid nitrogen to serve as stock tumor. For each experiment a vial was thawed, the cells
were washed in PBS and 2 X 106 of them used to initiate peritoneal ascites tumors in
semisyngeneic F1 hybrid mice. After 6 d of growth, the tumor cells were harvested in
heparinized PBS, washed, and resuspended in PBS. In all experiments, tumors were
initiated by injecting 106 tumor cells in a volume of 50 yl of PBS.
Generation and Passive Transfer ofDTHandIts Suppression.
￿
To induce a state of DTH,
mice were immunized by intradermal injection of an admixture of 3 X 106 Meth A cells
and 50 jag of Propionibacterium acnes (formal in-killed Corynebacterium parvum from
Burroughs Wellcome Co., Research Triangle Park, NC). This is known to result in a
tumor that grows for 8-9 d then undergoes regression, leaving the animals immune to
growth of a subsequent implant of tumor cells (7) and capable of mounting a DTH
reaction to intrafootpad injection of Meth A cells (see later section). For passive transfer
of DTH, the spleens of immunized mice were diced into small pieces, and the pieces were
gently pushed through a 50-mesh stainless steel screen into PBS containing I % FCS. The
resulting cell suspension was triturated with a pasteur pipette to break up clumps, and
passed through six layers of sterile surgical gauze to remove cell debris. The cells were
washed twice in PBS, suspended in PBS containing 1 % syngeneic mouse serum, and 1 ml
of the cell suspension containing 1 .5 spleen equivalents (about 1 .5 X 108 cells) was infused
into appropriate recipients via a lateral vein.
Mice bearing a progressive Meth A tumor were used as donors of suppressor cells.
Spleen cells were harvested from these mice at different times after initiating the tumor
intradermally in the belly region with 106 Meth A cells in 50 kl of PBS. To test for the
presence of suppressor T cells, 1 .5 organ equivalents (-1 .5 X 108) of spleen cells from
tumor-bearing donors were infused into recipients that had been infused 1 h earlier with
1 .5 organ equivalents (^-1 .5 X 108) of sensitized spleen cells from immunized donors. An
eliciting intrafootpad injection of 2 X 106 mitomycin c-treated Meth A cells in 50 U1 of
PBS was then given, and DTH was monitored over the next 48 h by measuring increases
in footpad thickness with dial calipers (Schnelltaster H.C . Droplin, Hessen, Federal
Republic of Germany).
Passive Transfer of Immunity and Its Suppression.
￿
The assay for determining theDiGIACOMO AND NORTH
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presence of tumor-induced suppressorT cells that suppress protective immunity has been
described elsewhere (2, 3). It involves showing that splenic T cells from tumor-bearing
donors can, on passive transfer, inhibit the ability of passively transferred immune T cells
to cause regression of a palpable 4-d tumor in T cell-deficient recipients. Briefly, donors
of immune T cells were immunized by injecting them with an admixture of 3 X 106 living
tumor cells and C. parvum as described for DTH above. T cell-deficient, tumor-bearing
test recipients received one organ equivalent (1 .5-2 .0 X 108) of immune spleen cells,
followed 3 h later by one organ equivalent (1 .5-2.0 X 108) of suppressor spleen cells from
mice bearing a progressive tumor. The test recipients were made T cell-deficient at 3 wk
of age by thymectomy followed 1 wk later by lethal (950 rad) 'Y-irradiation. They were
infused with 10' syngeneic bone marrow cells immediately after irradiation, and used in
experiments no sooner than 4 wk later.
Antibody Treatment.
￿
A hybridoma secreting anti-Ly-1 .2 mAb (CP30) was a gift from
Dr . Jan Klein, Max Planck Institute, Tubingen, Federal Republic of Germany. Anti-Ly-
2 .2 mAb was generated by a hybridoma (TIB-150) obtained from American Type Culture
Collection (Rockville, MD). Anti-L3T4a mAb (8) produced by hybridoma GK-1 .5 was
obtained from Dr. M. J. Bevan, Scripps Clinic, La Jolla, CA. All hybridomas were grown
to 5 X 105 cells/ml in RPMI 1640 medium (Gibco Laboratories, Grand Island, NY)
containing 10% FCS and antibiotics. The cultures were centrifuged to pellet the cells and
debris, and the supernatants were dispensed in small volumes and stored at -20'C until
needed. We used rabbit serum as a source of complement. It was obtained from rabbits
bred at the Trudeau Institute and selected on the basis of minimal cytotoxicity of their
serums for mouse thymocytes. For deletion of T cell subsets, spleen cells were incubated
at 2 X 10'/ml in a 1 :5 dilution of the appropriate antibody supernatant at 4°C for 45
min, and then in a 1 :10 dilution of rabbit serum at 37°C for 60 min, as described
elsewhere (2, 3).
Cyclophosphamide Treatment.
￿
Cytoxan was obtained from Mead Johnson & Co. (Evans-
ville, IN) and dissolved in sterile saline (15 mg/ml). Freshly prepared solutions were
injected intravenously into tumor-bearing suppressor donors 24 h before their lymphoid
cellswere harvested for passive transfer.
Results
Generation ofDTH to Tumor Antigens and Its Passive Transfer.
￿
To test tumor-
bearers for cells that suppress DTH, it was first necessary to show that true DTH
is generated in response to the Meth A tumor. This required showing that a
Meth A-immunized host can mount an inflammatory reaction to an injection of
Meth A cells and that the reaction has delayed kinetics. It also required showing
that the ability to mount the reaction can be passively transferred to recipients
with Ly-1 +,2-, L3T4a+ T cells.
It can be seen in Fig. 1 that when mice were injected intradermally with an
admixture of 3 X 106 living Meth A cells and C. parvum, they developed a
palpable tumor which grew for 8-9 d and then underwent complete regression.
It can also be seen that when these mice were challenged in a hind footpad with
an eliciting dose of 2 X 106 mitomycin c-treated Meth A cells, they had an 18-h
inflammatory reaction, the size of which depended on the time of tumor growth
or regression that the eliciting injection of tumor cells was given. The ability to
mount an inflammatory reaction was acquired by day 3 of immunization, peaked
on day 8, and then progressively decayed until about day 20 when the mice were
left with a relatively low, but stable state of sensitivity that lasted beyond 30 d of
immunization.
Fig. 2 shows that the intrafootpad inflammatory reaction described above had
the kinetics of a DTH reaction. It can be seen that when mice were given an1182
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FIGURE 1 .
￿
Immunization for DTH by intradermal injection of an admixture of 3 X 106
tumor cells and 100 ug of C. parvum resulted in 8-9 d of growth of the immunizing tumor
that emerged, followed by complete tumor regression (top). The ability to mount an 18-h
DTH reaction to an intrafootpad injection of 2 X 106 mitomycin c-treated tumorcells(bottom)
wasacquired progressively during the first 8dof immunization, peaked immediately before a
tumor regression, and then progressivelydecayedto a stable level from day 21 on. Meansand
SEM of five mice are shown.
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FIGURE 2.
￿
Time course of development of the expression of a DTH reaction to an intra-
footpad injection of 2 x 106 mitomycin c-treated tumor cells given on day 8 (peak) of
immunization, as shown in Fig. 1. It is obvious that the reaction had delayed kinetics. Means
and SEM of five mice are shown.DiGIACOMO AND NORTH
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FIGURE 3 .
￿
The ability of immunized mice to express a DTH reaction could be passively
transferred to normal recipients with donor lymphoid cells. The lymphocytes that transferred
immunity were Ly-1',2 - , L3T4' T cells, in that they were destroyed by treatment with anti-
Ly-1 antibody, or anti-L3T4 antibody and complement, but not by anti-Ly-2 antibody and
complement . In this experiment donor spleen cells were harvested on day 8 ofimmunization,
and the recipients received the eliciting dose of mitomycin c-treated tumor cells 1 h after
receiving donor cells. Means and SEM of five mice per group are shown .
intrafootpad injection of mitomycin c-treated tumor cells on day 8 of immuni-
zation there was minimal footpad swelling at 3 h, maximum swelling at 18 h,
and then a progressive decrease in footpad thickness . Additional evidence that
the reaction was true DTH is shown in Fig . 3, where it can be seen that the
ability to mount the reaction could be passively transferred from immunized
mice to normal recipient mice with spleen cells . Fig . 3 also shows that the
responsible cells were of the Ly-1',2- , L3T4+ helper phenotype, in that their
ability to transfer DTH was eliminated by treatment with either anti-Ly-1 .2
antibody and complement, or anti-L3T4a antibody and complement, but not by
treatment with anti-Ly-2.2 antibody and complement.
Spleen Cells from Mice Bearing a 6-d Tumor, But Not a 16-d Tumor, Suppress
Expression of Passively Transferred DTH. According to the results of others,
lymphoid cells obtained from mice bearing the syngeneic S1509a sarcoma (4, 5)
or Meth A fibrosarcoma (6) can, upon passive transfer, suppress DTH reactions
to these tumors in appropriately immunized recipients . To determine whether
similar suppressor cells are generated in response to the Meth A tumor under
study in this laboratory, an attempt was made to suppress passively transferred
Meth A-specific DTH with spleen cells from donors bearing a progressive Meth
A tumor . This involved infusing spleen cells from suppressor donors bearing
either a 6-d, or 16-d, progressive MethA tumor into recipients that had received
spleen cells from immunized donors 1 h earlier . The recipients were then
challenged in a hind footpad with mitomycin c-treated Meth A cells . The
sensitized T cells for transferring DTH were harvested from donors with peak
DTH on day 8 of immunization with the C. parvum-tumor cell admixture, as
shown in Fig . 1 .
It can be seen in Fig . 4 that spleen cells from mice bearing a 6-d Meth A tumor
could, on passive transfer, suppress the expression of passively transferred DTH1184
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FIGURE 4.
￿
The expression of passively transferred DTH was suppressed by passive transfer
of spleen cells from donormice bearing a day 6 (5 mm diameter) tumor, butnot from donors
bearing a day 16 (12 mm diameter) tumor . Suppressor cells were transferred 1 h after
transferring sensitized T cells, and 2 h after challenging the recipients with antigen . Means
andSEM of five mice pergroupare shown . Asterisk indicatesp<0.05 . Supp, suppressor cells.
in naive recipients . On the other hand, spleen cells from donors bearing a 16-d
Meth A tumor failed to significantly suppress the expression of passively trans-
ferredDTH in a similar group of recipients . Therefore suppressors ofDTH are
acquired during early stages ofgrowth of the Meth A fibrosarcoma, but are not
present in significant numbers at later stages of tumor growth when Ly-1 + ,2-
suppressor T cells that can suppress the expression of adoptive immunity are
acquired (2, 3) .
The consequences of infusing suppressor cells on the kinetics ofdevelopment
of the DTH reaction is clearly illustrated by the results ofan additional experi-
ment shown in Fig . 5 . These results leave no doubt that spleen cells from donors
with a 6-d tumor, but not a 16-d tumor, had a profound suppressive effect on
the DTH reaction from an early stage of its development.
Membrane Phenotype and Cyclophosphamide Sensitivity of Suppressors ofDTH.
Fig . 6 shows that when cells from 6-d tumor-bearing donors were treated with
anti-Ly-2.2 antibody and complement, their ability, on passive transfer, to sup-
pressaDTH reaction in recipients of sensitized T cells was completely abolished .
In contrast, treatment with anti-Ly-1 .2 mAb and complement had no effect on
the ability of the cells to suppress DTH. Thus, in keeping with the findings of
others (4-6), spleen cells from a 6-d tumor bearer that suppress the expression
of passively transferred DTH bear the Ly1-,2+ membrane phenotype .
These suppressors also proved highly sensitive to cyclophosphamide, in that a
single dose of 20 or 100 mg/kg given intravenously to mice bearing a 6-d Meth
A tumor caused complete elimination ofT cells that could, upon passive transfer,
suppress the expression of passively transferred DTH (Fig . 7) .
Kinetics of Generation of T Cells that Suppress DTH and T Cells that Suppress
Adoptive Immunity. By using the assay for suppression ofDTH described above,
it was possible to follow the kinetics of generation ofT cells that suppress DTH
against time of tumor growth . Fig . 8 shows that cells that can, upon passive
transfer, suppress the expression of passively transferredDTH were firstdetectedE
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FIGURE 5.
￿
Kinetics of development of an intrafootpad DTH reaction in adoptively immu-
nized recipients, andin adoptively immunizedrecipients that received spleen cellsfrom donors
bearinga day 6 or day 16 tumor. Suppressor cells from donors with a day 6 tumor blocked
theDTH reaction at anyearly stage of its development. In contrast, spleen cells from donors
with a day 16 tumor hadno suppressive effect. Means offive mice pergroupare shown. Cells
transferred: (O) immune, (A) immune + 6-d suppression, (") immune + 16-d suppression.
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FIGURE 6.
￿
Time course of generation of DTH suppressors in the spleen during tumor
growth. Cells that could suppress a DTH reaction in adoptively immunized recipients upon
passive transfer were generated progressively during the first 6 d of tumor growth, and were
then progressively lost. Meansof five mice pergroupare shown.
in the spleens of tumor-bearing donors around day 3 of tumor growth, reached
maximum production on about day 6, and declined progressively in number
thereafter.
In contrast, the generation of suppressor T cells that could suppress adoptive
immunity against an established tumor in T cell-deficient recipients occurred
much later. Fig. 9 serves to confirm results previously published (2, 3) by showing
that spleen cells that can, upon intravenous infusion, inhibit the ability of1186 T CELL SUPPRESSORS OF ANTITUMOR IMMUNITY
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￿
The suppressor spleen cells from a day 6 tumor bearer that could suppress the
expression of DTH in an adoptively immunized recipient, proved to be Ly-1-,2+T cells. Their
ability to passively transfer suppression was eliminated by treatment with anti-Ly-2 antibody
plus complement, butnot by treatment with anti-Ly-1 antibody and complement. Means and
SEM of five mice pergroup are shown. Asterisk indicates p < 0.05, double asterisk indicates
p < 0.01. CY, cyclophosphamide.
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￿
Suppressor T cells in donors bearing a day 6 tumor were eliminated by treating
the donors with 100 or 20 mg/kg of cyclophosphamide 24 h before harvesting their spleen
cells. MeansandSEM of five mice per group are shown. Asterisk indicatesp < 0.05.
intravenouslyinfusedimmune T cells to cause regression ofan established tumor
in T cell-deficient recipients were not acquired progressively in the spleens of
tumor bearers until after 9-12 d of tumor growth. Therefore, at a time when
the host possesses maximal numbers of T cells that can suppress DTH (Fig. 8),
it does not possess T cells that can suppress the expression ofadoptive immunity
in a Tcell-deficient recipient.
T Cells that Suppress DTH Do Not Suppress Immunity in the Same Recipients.
￿
It
was shown above that T cells from day-6 Meth A bearers can convincingly
suppress, on passive transfer, the expression ofpassively transferred DTH, but
not the expression ofpassively transferred immunity against an established tumor
in T cell-deficient recipients. This indicated the distinct possibility that suppres-
sion of DTH is not the same as suppression ofprotective immunity. Therefore,
it was important to determine, with the Meth A tumor under study in this100
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￿
Time course of generation of T cells that suppresses the expression of adoptive
immunity against an established tumorin T cell-deficient recipients. The left panel shows the
results of infusing T cell-deficient recipient mice bearing a 4-d tumor with one organ
equivalent (1 .5 X 108) of spleen cells from immune donors (IMM. CONT.), or with one organ
equivalent of spleen cells from immunized donors plus one organ equivalent of spleen cells
from donors bearing a 6-, 9-, 12-, 15-, or 18-d tumor (numbers on individual graphs). It can
be seen that T cells that could suppress the function of immune T cells were not acquired
progressively until after day 9 of growth of the donor tumor. The right panel shows the same
resultsexpressed in termsof changes against time of tumorgrowth in an index of suppression
that was obtained by subtracting the size of the time in recipients of immune cells alone from
its size in the recipients of immune cells plus suppressor cells on day 23 of the experiment.
Meansof five mice pergroupareshown.
laboratory, whetherTcell suppressors of DTH can suppress immunity to growth
of a tumor implant. It can be seen in Fig. 10 that injection of 2 X 106 living
tumor cells into the hind footpad of immunized mice resulted in the emergence
of a tumor that grew briefly and then underwent complete regression. It can be
seen, in addition, however, that growth of the implant involved a substantial
increase in footpad thickness during the first 18 h of challenge, which did not
occur in unimmunized control mice. Therefore, the swelling at 18 h was not due
to tumor growth, but to a DTH reaction to the challenge implant. This was
evidenced by the additional finding that the same 18-h swelling reaction occurred
in response to injection ofthe same number ofmitomycin c-treated tumor cells.
Indeed, if immunized mice were infused with suppressor cells from a day 6
tumor bearer immediately before being given the living challenge implant, the
18-h DTH reaction was essentially suppressed. However, this suppression of
DTH in no way interfered with the expression of immunity to growth of the
same implant. Therefore, under the conditions used, suppression of DTH did
not result in the suppression of the host's ability to express antitumor immunity
at the same site.
. N
Two models ofT cell-mediated suppression ofantitumor immunity have been
studied in some detail. One is based on the capacity of T cells from tumor-1188
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￿
Evidence that suppression of DTH did not result in suppression of immunity.
Passive transfer of suppressor cells from donors with a day 6 tumor failed to suppress the
ability of immunized mice to express immunity against an intrafootpad implant of 2 x 106
living tumor cells, even though the 18-h DTH reaction to the living implant was severely
suppressed. The 18-h increase in footpadthickness that resulted from implanting living tumor
cells was identical to the increase in footpad thickness that resulted from implanting the same
number of mitomycin c-treated tumor cells (DTH CONTROL). Regardless of whether or not
they received T cell suppressors of DTH, the immunized recipients could cause complete
regression of the tumor that emerged from the implant. In contrast, the tumorimplant grew
progressively in normal mice. Meansof five mice pergroupare shown. Supp, suppressor cells.
bearing donors to suppress, upon passive transfer, the expression of a tumor-
specific DTH reaction to an injection of tumor cells in tumor-immunized recip-
ients. The other is based on the capacity of T cells from tumor bearers to
suppress, upon passive transfer, the expression ofadoptive immunity against an
established tumor in T cell-deficient recipients. The tumor on which the first
mentioned model is based isthe S1509a sarcoma syngeneic in A/J mice (reviewed
in 4), although similar results have been published more recently with the
BALB/c Meth A fibrosarcoma (6, 9). According to studieswith thesetwo tumors,
T cells that can suppress a tumor-specific DTH reaction in immunized recipients
are produced very early (24-48 h) after implanting tumor cells subcutaneously,
increase in number to peak around days 6-7 of tumor growth, and are then
progressively lost as the tumor grows larger in size. These suppressors display
the Ly-1-,2+, IJ+ membrane phenotypeandare functionally eliminated bygiving
the host as little as 20 mg/kg of cyclophosphamide.
The second major model of tumor-induced suppression is based on the ability
of T cells from tumor-bearing donors to inhibit, on passive transfer, the expres-
sion of passively transferred immunity against a relatively large palpable tumor
in T cell-deficient recipient mice . This model of suppression of immunity
developed from the initial finding in this laboratory (10) that tumor-sensitized T
cells from immunized donor mice failed, on passive transfer, to cause regression
of a recipient tumor, unless the recipient had been made T cell-deficient byDiGIACOMO AND NORTH
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thymectomy and irradiation. It was reasoned that sensitized T cells express their
function in T cell-deficient recipients, but not in immunocompetent recipients,
because the latter recipients acquired suppressor Tcells in response to progres-
sive growth of their tumor. Evidence consistent with this interpretation was
supplied by the demonstration that the obstacle to adoptive immunotherapy
could be passively transferred. In other words, it was shown (10, 11) that an
infusion of T cells from tumor-bearing donors, but not from normal donors,
could suppress the ability of Tcells from immunized donors to cause regression
of a palpable tumor in T cell-deficient recipients. It was shown later (12) that
the suppressor Tcells detected by this assayare specific for the tumor that evokes
their generation. Moreover, they are different in a number of ways from the
suppressor T cells that function to suppress tumor-specific DTH. For example,
unlike the suppressor of DTH, the suppressors ofadoptive immunotherapy bear
the Ly-1+,2- membrane phenotype, and are not generated until late in tumor
growth, when the tumor grows beyond about 8 mm in diameter (2, 3). More
recent studies show (A. DiGiacomo and R. J. North, manuscript submitted for
publication) that these suppressor T cells also display the L3T4 antigen. Again,
the suppressors of adoptive immunotherapy used against an established tumor
are not as sensitive to cyclophosphamide as the suppressors of DTH. Whereas,
as shown here and elsewhere (9), suppressors of Meth A-specific DTH are
destroyed by a 20 mg/kg dose of the drug, it requires a 100 mg/kg dose to
destroy the suppressors ofadoptive immunity (13).
However, in spite ofthe differences between these two types ofsuppressor T
cells, this study leaves no doubt that both types are produced in response to the
Meth A fibrosarcoma under study in this laboratory. The results show that Ly-
1-,2+ suppressor T cells defined by their ability to suppress DTH are generated
progressively during the first 6 d of tumor growth, whereas suppressor T cells
that can suppress the expression of adoptive immunity are generated later in
tumor growth when the production of the suppressors of DTH is on the wane.
There is a need, therefore, to discuss the functional significance ofeach type of
suppressor Tcell, with a view to deciding how each type might explain downreg-
ulation of the antitumor immune response.
In this regard, it can be stated first, that because the reason for postulating
the existence of suppressor T cells in tumor-bearing mice is to explain how
tumors avoid being destroyed by an antitumor immune response, suppressor
cells that can suppress a proven antitumor effector mechanism in vivo are likely
to be more important than those that suppress the expression of a correlate of
immunity, like DTH. It should be mentioned, however, that the T cell suppres-
sors of DTH induced by the S1509a sarcoma were originally defined in terms
of their ability to partly suppress the expression of immunity to growth of a
tumor implant in immunized recipients (14). More recently published findings
(6) with the Meth A fibrosarcoma indicate, nevertheless, that suppression of a
DTH reaction to this tumor by passively transferred Ly-1-,2+ suppressors may
not necessarily be associated with suppression ofimmunity. The results presented
here serve to show that this is the case. They reveal that, although T cell
suppressors of DTH can efficiently suppress a DTH reaction to an implant of
living tumor cells in immunized recipients, they fail to suppress, to any extent,1190
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the expression of immunity to growth ofthe same implant. At this stage of the
investigation, therefore, it is difficult to see a role for the T cell suppressors of
tumor-specific DTH in the escape of the immunogenic Meth A fibrosarcoma
from immunity.
Even so, the fact that suppressor Tcells that can suppress tumor-specific DTH
reaction in immunized recipients are generated in response to tumor growth,
means that these suppressors must play some part in the antitumor immune
response. There can be little doubt that the sensitivity reaction that these
suppressors suppress is true DTH, because it was shown here that it develops
with delayed kinetics and is mediated by Ly-l+,2-, L3T4a' T cells. However, it
needs to be appreciated that the DTH described here and elsewhere (4-6, 9)
was induced by immunization, rather than by progressive tumor growth. To
understand the meaning of suppression of DTH, we need to first determine
whether tumor-specific DTH represents a mechanism of tumor rejection, and
second, whether it can develop in a tumor-bearing animal in the absence of
suppressors of DTH. Presumably such evidence will be forthcoming. In the
meantime, an explanation of tumor escape based on suppression ofconcomitant
immunity by Ly-1+,2- suppressor T cells seems relatively easy to accept, because
these suppressors have the capacity to suppress a mechanism of immunity that
can cause the regression of a relatively large tumor mass. They have the same
surface phenotype (2, 3) as the T cells that can passivelytransfer immunosuppres-
sion in other in vivo models of antitumor immunity (13, 14), and that can
passively transfer tolerance to allografts in rats (15). The possibility that these
suppressor T cells are "inducer suppressors," that recruit Ly-1-,2+ "effector
suppressors" that ultimately express suppression is worth considering, but has
been questioned (1, 17). In any case, it would not explain why suppression of
DTH by Ly-1-,2+ suppressor T cells is not associated with suppression of
immunity.
Summary
The results of this study show that during growth of the immunogenic Meth
A fibrosarcoma, two different types ofsuppressor T lymphocytes are generated
in sequence. One type is generated during early tumor growth, reaches peak
number around day 6, and is progressively lost thereafter. It is defined by its
ability, upon passive transfer, to suppress the expression of a DTH reaction to
tumor antigens in tumor-immunized recipients. It bears the Ly1-,2+ membrane
phenotype and is sensitive to relatively low doses of cyclophosphamide. In
contrast, the second type of suppressor cell is not detected until after day 9 of
tumor growth, and is defined by its ability to inhibit, upon passive transfer, the
expression ofadoptive immunity againstan established tumor in T cell-deficient
recipients. According to previousstudies it bears the Lyl+,2-, L3T4a+membrane
phenotype and is less sensitive to cyclophosphamide than the T cell suppressor
of DTH. It is argued that this second type of suppressor T cell seems likely to
be responsible for the escape ofimmunogenic tumors from antitumor immunity,
because it can suppress the expression of a powerful mechanism of antitumor
immunity in recipient mice, and is generated progressively as the tumor-bearing
host loses concomitant immunity. In contrast, although the Ly-l-,2+ T cellDiGIACOMO AND NORTH
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suppressors of DTH can efficiently suppress a DTH reaction to an implant of
living tumor cells, they fail to suppress the expression of immunity to the same
implant.
Receivedfor publication 29 May 1986 and in revised form 26June 1986.
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